BioWorld

Jan. 28, 2010

Alnara Raises $35M Series B as PERTly Liprotamase Nears NDA

Alnara Pharmaceuticals Inc. is expected to announce Thursday morning the close of a $35 million Series B financing, which will support launch preparations for pancreatic enzyme replacement therapy (PERT) liprotamase. (BioWorld Today) Read More

Gilead Earnings Rise on Atripla, Truvada Sales

Profiling Methods Give Broader View in Basic, Clinical Studies

Government Work 'Easy Money'? Don't Bet Your R&D Budget on it

GenVec Raises $28M on Heels of Novartis Gene Therapy Deal

Spectrum Terminates Ozarelix BPH Program, Saving $40M

Clinic Roundup

Other News To Note

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 10, 2026